Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus: The ADVANCE Trial

@article{Ohkuma2019AcuteII,
  title={Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus: The ADVANCE Trial},
  author={Toshiaki Ohkuma and Min Jun and Anthony Rodgers and Mark Emmanuel Cooper and Paul P. Glasziou and Pavel Hamet and Stephen B Harrap and Giuseppe Mancia and Michel Marre and Bruce Neal and Vlado Perkovic and Neil R. Poulter and Bryan Williams and Sophia Zoungas and John Chalmers and Mark Woodward},
  journal={Hypertension},
  year={2019},
  volume={73},
  pages={84–91}
}
Discontinuation of angiotensin-converting enzyme (ACE) inhibitor is recommended if patients experience ≥30% acute increase in serum creatinine after starting this therapy. However, the long-term effects of its continuation or discontinuation on major clinical outcomes after increases in serum creatinine are unclear. In the ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation), 11 140 diabetes mellitus patients were randomly… 

Figures from this paper

Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality: Results from a Randomized Controlled Trial of ACE Inhibitors.

TLDR
Continuation of angiotensin-converting enzyme inhibitor-based therapy consistently decreased the subsequent risk of clinical outcomes, including cardiovascular and kidney outcomes and death, regardless of short-term changes in serum potassium.

Association of Acute Increases in Plasma Creatinine after Renin-Angiotensin Blockade with Subsequent Outcomes.

TLDR
Among real-world monitored adults, increases in creatinine (>10%) after initiation of RASi are associated with worse health outcomes, and these results suggest that patients with increases inCreatinine have higher subsequent risk of cardiovascular and kidney outcomes.

Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial.

TLDR
In people with type 2 diabetes and CKD, use of canagliflozin results in early, sustained reductions in albuminuria, which were independently associated with long-term kidney and cardiovascular outcomes.

Rising serum potassium and creatinine concentrations after prescribing renin–angiotensin–aldosterone system blockade: how much should we worry?

  • F. Assadi
  • Medicine
    World Journal of Pediatrics
  • 2021
TLDR
The limited initial rise in serum creatinine level following RAAS inhibition is reversible and stabilizes within 2 months following therapy with RAAS initiation, and stopping ACEI or ARB based on these findings would be a mistake.

Renin-Angiotensin System Blockade in Advanced Kidney Disease: Stop or Continue?

Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial

TLDR
Data indicate that eGFR variability predict changes in the risk of major clinical outcomes in T2D, with evidence of a positive linear trend.

Impact of early glomerular filtration rate decline in response to antihypertensive treatment on risk of end-stage kidney disease and cardiovascular outcomes: a systematic review and meta-analysis

TLDR
It is concluded that major reductions in the glomerular filtration rate occurring soon after starting angiotensin-converting enzyme inhibitors/angiotENSin receptor blockers and/or under intensive blood pressure control predict end-stage kidney disease.

The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study

TLDR
This study supports the utility of eGFR slope in type 2 diabetes as a surrogate endpoint for renal outcomes, as well as a prognostic factor for identifying individuals at high risk of cardiovascular disease and all-cause mortality.

eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined.

TLDR
It is not surprising that the major SGLT2i outcome trials have reported an early decline in eGFR shortly after initiating these drugs compared with placebo controls, but the aim is to put this observation into context, while providing clinicians with a practical approach to managing this scenario.

References

SHOWING 1-10 OF 24 REFERENCES

Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study

TLDR
Increases in creatinine after the start of angiotensin converting enzyme inhibitor/angiotens in receptor blocker treatment were associated with adverse cardiorenal outcomes in a graduated relation, even below the guideline recommended threshold of a 30% increase for stopping treatment.

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

TLDR
A strong association exists between acute increases in serum creatinine of up to 30% that stabilize within the first 2 months of ACEI therapy and long-term preservation of renal function and withdrawal of an ACEI in patients with preexisting renal insufficiency is recommended.

Prognostic Importance of Early Worsening Renal Function After Initiation of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Cardiac Dysfunction

TLDR
Early WRF in the setting ofACE-I initiation appears to represent a benign event that is not associated with a loss of benefit from continued ACE-I therapy, and these data support the notion that the mechanism underlying WRF is important in determining its prognostic significance.

Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction: Insights From the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study

TLDR
In patients with heart failure after acute myocardial infarction and receiving standard medical care, an early decline in eGFR is not uncommon and is associated with poor long-term outcome, and eplerenone induced a moderately more frequent early decline, which did not affect its clinical benefit on cardiovascular outcomes.

Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction.

TLDR
Monitoring serum creatinine in patients during the first few weeks after MI may help to identify those who are at highest risk and guide effective long-term therapeutic choices.

A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function.

TLDR
An initial fall in GFR after starting antihypertensive treatment in patients with a mild to moderate renal function impairment is reversible even after years of treatment, suggesting that this therapy-induced fall is of hemodynamic and not of structural origin.

Interaction between baseline and early worsening of renal function and efficacy of renin–angiotensin–aldosterone system blockade in patients with heart failure: insights from the Val‐HeFT study

TLDR
The effect of (dual) renin–angiotensin–aldosterone system (RAAS) blockade with valsartan and an ACE inhibitor with reduced EF on cardiovascular death and HF hospitalization by subgroups and by presence of early worsening of renal function (EWRF) is evaluated.